Review Article
Developing Multipurpose Reproductive Health Technologies: An Integrated Strategy
Table 4
Reproductive Health Consensus Target Product Profile for MPT Vaccines.
| Parameter | Optimally preferred |
| Indication and mechanism | HSV, HIV, HPV Systemic and mucosal protective concentrations of neutralizing antibodies (and cell-mediated immunity) | Target population | Women/girls: developed and developing regions | Immunogen, adjuvant, and delivery modes | Well-characterized immunogens (but range of adjuvants and delivery modes | User-action | Pharmacy or self-administered boosts | Boost schedule | Mucosal boost schedule uncertain | Typical use efficacy | HSV (70–90%); HIV (70–90%); HPV (>95%) | Side effect profile | Minimal | Additional benefits | Versatile production platform | Shelf life | Years | Storage needs | No cold chain required | Price | $1/dose | Infrastructure | Pharmacy |
|
|